1. Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial - the MIRO trial
- Author
-
Michel Prudhomme, Jean-Yves Mabrut, Denis Collet, Franck Bonnetain, Renaud Flamein, Nicolas Carrere, Christophe Mariette, Guillaume Piessen, Bernard Meunier, Thierry Perniceni, Cécile Brigand, Frédérique Peschaud, N. Briez, Simon Msika, Christophe Doddoli, Jean-Pierre Triboulet, Département de chirurgie digestive et cancérologique, Centre Hospitalier de Verdun, Faculté de médecine Henri Warembourg, Université de Lille, Droit et Santé, Centre d'épidémiologie des populations ( CEP ), Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Département de chirurgie digestive, CHU Strasbourg, Chirurgie Générale et Digestive [Purpan], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Bordeaux [Bordeaux], Hôpital Nord [CHU - APHM], CHU Clermont-Ferrand, Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), CHU de Pontchaillou, CHU Louis Mourrier, Institut Mutualiste de Montsouris ( IMM ), Service de chirurgie générale, digestive et oncologique, Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Ambroise Paré, Centre Hospitalier Régional Universitaire de Nîmes ( CHRU Nîmes ), the Programme Hospitalier de Recherche Clinique from the French National Cancer Institute (INCA), Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, CHU Toulouse [Toulouse], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Institut Mutualiste de Montsouris (IMM), Service de chirurgie générale, digestive et oncologique [CHU Ambroise-Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Chirurgie Hépatobiliaire et Digestive [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], BMC, Ed., Faculté de Médecine Henri Warembourg - Université de Lille, and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
- Subjects
Cancer Research ,Esophageal Neoplasms ,medicine.medical_treatment ,Kaplan-Meier Estimate ,030230 surgery ,law.invention ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,surgery ,Study Protocol ,0302 clinical medicine ,Randomized controlled trial ,law ,Prospective Studies ,Prospective cohort study ,minimally invasive surgery ,Standard treatment ,Stomach ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,3. Good health ,Thoracotomy ,Oncology ,Esophagectomy ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Adult ,medicine.medical_specialty ,oesophageal cancer ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Adenocarcinoma ,lcsh:RC254-282 ,Young Adult ,03 medical and health sciences ,Stomach surgery ,Esophagus ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,oesophagectomy ,Preoperative Care ,Genetics ,medicine ,Humans ,Aged ,Postoperative Care ,business.industry ,General surgery ,Postoperative complication ,Surgery ,Clinical trial ,Lymph Node Excision ,Laparoscopy ,Lymphadenectomy ,business ,randomised controlled trial ,Follow-Up Studies - Abstract
Background Open transthoracic oesophagectomy is the standard treatment for infracarinal resectable oesophageal carcinomas, although it is associated with high mortality and morbidity rates of 2 to 10% and 30 to 50%, respectively, for both the abdominal and thoracic approaches. The worldwide popularity of laparoscopic techniques is based on promising results, including lower postoperative morbidity rates, which are related to the reduced postoperative trauma. We hypothesise that the laparoscopic abdominal approach (laparoscopic gastric mobilisation) in oesophageal cancer surgery will decrease the major postoperative complication rate due to the reduced surgical trauma. Methods/Design The MIRO trial is an open, controlled, prospective, randomised multicentre phase III trial. Patients in study arm A will receive laparoscopic-assisted oesophagectomy, i.e., a transthoracic oesophagectomy with two-field lymphadenectomy and laparoscopic gastric mobilisation. Patients in study arm B will receive the same procedure, but with the conventional open abdominal approach. The primary objective of the study is to evaluate the major postoperative 30-day morbidity. Secondary objectives are to assess the overall 30-day morbidity, 30-day mortality, 30-day pulmonary morbidity, disease-free survival, overall survival as well as quality of life and to perform medico-economic analysis. A total of 200 patients will be enrolled, and two safety analyses will be performed using 25 and 50 patients included in arm A. Discussion Postoperative morbidity remains high after oesophageal cancer surgery, especially due to major pulmonary complications, which are responsible for 50% of the postoperative deaths. This study represents the first randomised controlled phase III trial to evaluate the benefits of the minimally invasive approach with respect to the postoperative course and oncological outcomes in oesophageal cancer surgery. Trial Registration NCT00937456 (ClinicalTrials.gov)
- Published
- 2011